Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

Peter
Rossing
MD, DMSc, Steno Diabetes Center, Denmark

Professor Peter Rossing is a clinician researcher devoted to complications in diabetes with a focus on renal and cardiovascular complications. He holds a specialist degree in internal medicine and endocrinology and is Chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes.

 


Professor Rossing has investigated key features of the pathophysiology of the diabetic kidney at different stages in epidemiological studies. He has identified several markers for development of diabetic nephropathy, making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.



Professor Rossing is a coordinator of the EU FP7 project PRIORITY, which aims to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON, which aims at personalising prevention of diabetic nephropathy.